These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21367625)

  • 1. RETRACTED: Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study.
    Derosa G; Maffioli P; D'Angelo A; Fogari E; Bianchi L; Cicero AF
    J Diabetes Complications; 2011; 25(4):258-66. PubMed ID: 21367625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load.
    Derosa G; Maffioli P; Ferrari I; Fogari E; D'Angelo A; Palumbo I; Randazzo S; Bianchi L; Cicero AF
    Eur J Pharmacol; 2011 Jan; 651(1-3):240-50. PubMed ID: 21118681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
    Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
    Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.
    Derosa G; Ragonesi PD; Carbone A; Fogari E; D'Angelo A; Cicero AF; Maffioli P
    Expert Opin Pharmacother; 2012 Dec; 13(18):2581-91. PubMed ID: 23121473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
    J Pharm Pharm Sci; 2010; 13(3):378-90. PubMed ID: 21092710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bonaventura A; Romano D; Maffioli P
    J Clin Lipidol; 2012; 6(6):553-64. PubMed ID: 23312051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance.
    Derosa G; Cicero AF; D'Angelo A; Ragonesi PD; Ciccarelli L; Fogari E; Salvadeo SA; Ferrari I; Gravina A; Fassi R; Fogari R
    Clin Drug Investig; 2006; 26(9):529-39. PubMed ID: 17163286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; D'Angelo A; Cicero AF
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study.
    Rachmani R; Bar-Dayan Y; Ronen Z; Levi Z; Slavachevsky I; Ravid M
    Diabetes Obes Metab; 2004 Jan; 6(1):63-8. PubMed ID: 14686965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus glibenclamide in patients with diabetes.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementation of α-linolenic acid improves serum adiponectin levels and insulin sensitivity in patients with type 2 diabetes.
    Gomes PM; Hollanda-Miranda WR; Beraldo RA; Castro AV; Geloneze B; Foss MC; Foss-Freitas MC
    Nutrition; 2015 Jun; 31(6):853-7. PubMed ID: 25933493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.